# NICE HealthTech guidance HTG630: PLGF-based testing to help diagnose suspected preterm pre-eclampsia

Guideline · id `maternal:pub-nice-htg630` · Maternal & Newborn Atlas · release `90bf3ae42cf8937c` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Browse, life stage: Pregnancy  

## In plain language

Tests that can be added to the usual clinical assessment to help plan care for someone with suspected pre-eclampsia from 20 weeks to 36 weeks 6 days of pregnancy. They measure placental growth factor (PlGF).

## Technical summary

NICE HealthTech guidance HTG630, published 27 July 2022 as diagnostics guidance DG49 and later moved to the HTG number. The Overview page says the recommendations and content were not changed by the move. Recommendation 1.1 covers PlGF-based tests added to the usual clinical examination for people with suspected preterm pre-eclampsia between 20 weeks and 36 weeks 6 days of pregnancy. Whether a later NICE edition replaces it was not checked. Because of NICE's reuse terms, this atlas states the facts in its own words, with a citation and a link.

## Connected pages

- Issued by: National Institute for Health and Care Excellence (NICE) (`maternal:nice`)

## Provenance

Content hash: 75b3203897097dd9575047babab82703430b10e23686c7e84858bd2e75a8d13c
Last substantive edit: 2026-10-14
Evidence last checked: 2026-10-14